Cargando…
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-yea...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6013558/ https://www.ncbi.nlm.nih.gov/pubmed/29963012 http://dx.doi.org/10.3389/fendo.2018.00318 |